Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data-Reference-Cited by-同舟云学术

Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data

Published:2018-06 Issue:6 Volume:24 Page:525-533
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Vogelzang Nicholas J.¹,Pal Sumanta K.²,Ghate Sameer R.³,Li Nanxin⁴,Swallow Elyse⁴,Peeples Miranda⁴,Zichlin Miriam L.⁴,Meiselbach Mark K.⁴,Perez Jose Ricardo³,Agarwal Neeraj⁵

Affiliation:

1. Comprehensive Cancer Centers of Nevada, Las Vegas.

2. City of Hope Comprehensive Cancer Center, Duarte, California.

3. Novartis Pharmaceuticals, East Hanover, New Jersey.

4. Analysis Group, Boston, Massachusetts.

5. Huntsman Cancer Institute, University of Utah, Salt Lake City.

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world study on the characteristics, post‐nephrectomy journey, and outcomes of patients with early‐stage renal cell carcinoma based on risk groups;Cancer Medicine;2024-06

2. Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents;Clinical Genitourinary Cancer;2022-10

3. Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study;Targeted Oncology;2022-06-25

4. Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma;Journal of Geriatric Oncology;2022-06

5. Provider‐ and patient‐level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma;Cancer Medicine;2021-09-04